Table 1.

Patient characteristics and peripheral blood progenitor cell product characterization

Patient Age (y) Histology Site StatusConsolidation cycle CD34 selectionCD34+ dose (×106/kg)T-cell dose (×106/kg) ANC <500 (days) PLT <5000 (days)
1  25  ESFT Primary: left ilium Mets: lung, bone, BM Progressed on therapy, DOD  6  −  7.8  33.6 10  24  
2  5  RMS  Primary: right foot Mets: lymph nodes  Recurrence 3 mo, DOD  6 7 8  − − −  6.1 6.1 6.1  6.0 6.0 6.0  9 8 7  24 22 19  
3  19  RMS  Primary: ethmoid sinus  NED 4.5 y 6 7 8  − − −  6.9 7.1 7.6  43.2 34.1 46.3  7 7 7  16 12 17  
4  15  RMS  Primary: paratesticular Mets: lung, bone  SMN 15 mo, died  6 7 8  − − −  7.7 14.3 15.4  12.7 16.2 11.9  8 6 7  16 25 48  
5  23  ESFT  Primary: left ilium Mets: lung  Recurrence 12 mo, DOD  6 7 8  − − −  30.4 27.9 29.5  36.4 33.0 19.8  8 6 6  14 13 13  
6  12  ESFT  Primary: right ilium Mets: bone  NED 5 y  6 7 8  − − −  5.5 5.9 5.9  3.3 4.4 4.4  9 9 9  29 20 33  
7  22  ESFT  Primary: right femur  NED 5 y 6 7  − −  9.4 9.4  64.1 64.1  7 9  16 19  
8  18  RMS  Primary: prostate Mets: bone  Recurrence 3 mo, DOD  6 7 8  − − −  23.2 22.0 23.8  9.3 8.7 10.5  6 6 5  14 15 16  
9  21  ESFT  Primary: Left ileum Mets: bone, BM  Recurrence 1 mo, DOD  6 7 8  − − −  11.7 3.2 1.61  149.0 129.0 214.0  7 13 12  21 74 N/A  
10  17  ESFT  Primary: C-spine  Recurrence 8 mo, DOD  6 7 8  + + +  18.7 9.4 32.0  0.1 0.0 0.5  6 6 7  12 13 12  
11  19  ESFT  Primary: left thigh Mets: lung  Recurrence 3 mo, DOD  6 7 8  + + +  10.3 10.3 10.3  0.1 0.1 0.1  8 7 7  9 12 22  
12  19  ESFT  Primary: humerus, Mets: lung  Recurrence 1 mo, DOD  6 7  + +  3.9 3.9  0.4 0.4  10 10  31 21  
13  14  RMS  Primary: vulva Mets: spine  Recurrence 2.5 y, DOD  6 7 8  + + +  5.6 5.6 5.6  0.1 0.1 0.1  9 9 9  21 25 10  
14  18  NB  Primary: suprarenal Mets: bone, BM, lymph nodes  Progressed on therapy, DOD 6  +  2.0  0.0  10  N/A  
15  20 RMS  Primary: abdominal wall  NED 3 y  6 7 8  + + +  17.6 17.6 17.6  0.5 0.5 0.5  7 5 6  13 10 15  
16  24  ESFT  Primary: left femur Mets: lung  Recurrence 1 mo, DOD  6 6* + +  4.9 1.5  0.4 0.0  9  >100  
17  14  EWS  Primary: right ileum NED 3 y  6 6* + +  9.4 9.4  0.1 0.1  7  >44  
18  15  EWS  Primary: right thigh NED 3 y  6  +  4.3  0.1  15  N/A 
19  17  EWS  Primary: pelvis Mets: lung  Recurrence 9 mo, DOD  6 7  + +  4.6 3.4  0.1 0.2  9 7  2 11 
Patient Age (y) Histology Site StatusConsolidation cycle CD34 selectionCD34+ dose (×106/kg)T-cell dose (×106/kg) ANC <500 (days) PLT <5000 (days)
1  25  ESFT Primary: left ilium Mets: lung, bone, BM Progressed on therapy, DOD  6  −  7.8  33.6 10  24  
2  5  RMS  Primary: right foot Mets: lymph nodes  Recurrence 3 mo, DOD  6 7 8  − − −  6.1 6.1 6.1  6.0 6.0 6.0  9 8 7  24 22 19  
3  19  RMS  Primary: ethmoid sinus  NED 4.5 y 6 7 8  − − −  6.9 7.1 7.6  43.2 34.1 46.3  7 7 7  16 12 17  
4  15  RMS  Primary: paratesticular Mets: lung, bone  SMN 15 mo, died  6 7 8  − − −  7.7 14.3 15.4  12.7 16.2 11.9  8 6 7  16 25 48  
5  23  ESFT  Primary: left ilium Mets: lung  Recurrence 12 mo, DOD  6 7 8  − − −  30.4 27.9 29.5  36.4 33.0 19.8  8 6 6  14 13 13  
6  12  ESFT  Primary: right ilium Mets: bone  NED 5 y  6 7 8  − − −  5.5 5.9 5.9  3.3 4.4 4.4  9 9 9  29 20 33  
7  22  ESFT  Primary: right femur  NED 5 y 6 7  − −  9.4 9.4  64.1 64.1  7 9  16 19  
8  18  RMS  Primary: prostate Mets: bone  Recurrence 3 mo, DOD  6 7 8  − − −  23.2 22.0 23.8  9.3 8.7 10.5  6 6 5  14 15 16  
9  21  ESFT  Primary: Left ileum Mets: bone, BM  Recurrence 1 mo, DOD  6 7 8  − − −  11.7 3.2 1.61  149.0 129.0 214.0  7 13 12  21 74 N/A  
10  17  ESFT  Primary: C-spine  Recurrence 8 mo, DOD  6 7 8  + + +  18.7 9.4 32.0  0.1 0.0 0.5  6 6 7  12 13 12  
11  19  ESFT  Primary: left thigh Mets: lung  Recurrence 3 mo, DOD  6 7 8  + + +  10.3 10.3 10.3  0.1 0.1 0.1  8 7 7  9 12 22  
12  19  ESFT  Primary: humerus, Mets: lung  Recurrence 1 mo, DOD  6 7  + +  3.9 3.9  0.4 0.4  10 10  31 21  
13  14  RMS  Primary: vulva Mets: spine  Recurrence 2.5 y, DOD  6 7 8  + + +  5.6 5.6 5.6  0.1 0.1 0.1  9 9 9  21 25 10  
14  18  NB  Primary: suprarenal Mets: bone, BM, lymph nodes  Progressed on therapy, DOD 6  +  2.0  0.0  10  N/A  
15  20 RMS  Primary: abdominal wall  NED 3 y  6 7 8  + + +  17.6 17.6 17.6  0.5 0.5 0.5  7 5 6  13 10 15  
16  24  ESFT  Primary: left femur Mets: lung  Recurrence 1 mo, DOD  6 6* + +  4.9 1.5  0.4 0.0  9  >100  
17  14  EWS  Primary: right ileum NED 3 y  6 6* + +  9.4 9.4  0.1 0.1  7  >44  
18  15  EWS  Primary: right thigh NED 3 y  6  +  4.3  0.1  15  N/A 
19  17  EWS  Primary: pelvis Mets: lung  Recurrence 9 mo, DOD  6 7  + +  4.6 3.4  0.1 0.2  9 7  2 11 

ESFT, Ewing sarcoma family of tumors; RMS, rhabdomyosarcoma; NB, neuroblastoma; DOD, dead of disease; NED, no evidence of disease; SMN, second malignant neoplasm; BM, bone marrow; Mets, metastases.

*

CD34 infusions that were administered subsequent to the initial infusion because of delayed hematopoietic recovery.

View Large